Verdict: Justified
Key finding: CYPH is a leveraged Zcash proxy. On the basic share count it looks like it trades below its ZEC holdings (~0.77x), but that ignores 80.8M pre-funded warrants ($0.001) and 76.0M warrants at $0.5335 from the October 2025 financing. Fully diluted it trades at ~1.7x net asset value: the stock price implies ZEC near $2,040 vs a spot price of about $1,151. The fall from $4.12 tracks ZEC and is not company news.
Scorecard
| Ticker | Rev last Q ($M) | Rev YoY last Q | Rev YoY prior Q | Gross margin (last Q, trend) | Op margin | EPS last Q vs yr ago | P/S | Mkt cap | 1-mo price % |
|---|---|---|---|---|---|---|---|---|---|
| CYPH | 0 | — | — | — | — | $0.25 vs -$0.40 | — | $289M (basic) | +1.6% |
| MSTR | 122.4 | +6.9% | +11.9% | 66.6% (flat) | — | -$24.07 vs $32.60 | ~113x | $56.2B | +4.6% |
| BMNR | 46.5 | — | +627.6% | 87.7% (up) | -25.5% | -$0.15 vs -$0.00 | ~208x | $12.8B | -13.6% |
| SBET | 11.5 | +1553.3% | +1525.7% | 97.8% (up) | 19.2% | -$1.88 vs -$4.27 | ~31x | $1.56B | -13.7% |
Latest reported quarters (CYPH, MSTR, SBET: Jun 30, 2026; BMNR: May 31, 2026). 1-month = Sep 14 to Oct 14 close. CYPH Q2 EPS per the 10-Q: $0.21 basic / $0.18 diluted, driven by a $46.0M embedded-derivative gain.
CYPH is the smallest and most leveraged name in the crypto-treasury group, and the only one built on Zcash. Revenue and margins mean little here: all four trade on their token holdings, so the ratio of market value to net asset value (mNAV) is the number that matters. Ethereum treasuries BMNR and SBET fell ~14% in a month; CYPH ended flat over the month but swung from $2.58 to $4.12 and back in between.
Move
- Aug 17 low $0.67 to Sep 25 close $4.12: about 6x in six weeks, alongside a ZEC rally (ZEC ~$768 on Aug 25 to ~$1,587 on Sep 27).
- Sep 25 to Oct 14: $4.12 to $2.62 (-36%) while ZEC fell to ~$1,166 (Oct 12).
- Oct 15: opened $2.43 (-7.3%), low $2.38, then reversed to about $2.69 (+2.5%) by late morning.
- 52-week range $0.39 to $4.19. The 50-day average is ~$2.22; the September base sits at $2.06-2.30.
Catalyst
- No CYPH-specific news found for October. The move is ZEC's price, amplified.
- What the company is: formerly Leap Therapeutics (cancer drugs, still run through its Leap subsidiary). In October 2025 it raised ~$59M in a private placement led by Winklevoss Capital and became a Zcash treasury company, with a goal of holding 5% of ZEC supply.
- Holdings: 323,394 ZEC at Jun 30, 2026 (average cost $341.83); 326,417.51 ZEC on the company dashboard as of Aug 31 (latest entry was 3,023 ZEC mined).
Sector: what the stock is worth vs its ZEC
| Item | Value |
|---|---|
| ZEC held (Aug 31) x spot ~$1,150.80 | ~$375.6M |
| Cash less liabilities (Jun 30) | ~+$4.0M |
| Cash from exercising the 76.0M warrants at $0.5335 | ~+$40.5M |
| Net asset value, fully diluted | ~$420M |
| Basic shares (Aug 10) | 107.76M |
| + pre-funded warrants ($0.001) | 80.77M |
| + warrants ($0.5335, exp. 2032) | 75.99M |
| Fully diluted shares | ~264.5M |
| NAV per fully diluted share | ~$1.59 |
| Price / NAV at $2.685 | ~1.7x |
At 1.0x NAV the share price would imply ZEC at about $1,151; at $2.685 it implies about $2,040. (inference) The premium is what makes CYPH swing harder than ZEC in both directions: +6x on the way up vs ZEC roughly 2x.
Risks
- Supply: a $200M at-the-market program with Cantor; ~22.2M shares (~$19.2M) sold in H1 2026, so most of it is still available. Selling stock at a premium to NAV is accretive for the company but adds supply into rallies.
- Warrant overhang: 156.7M pre-funded and $0.5335 warrants are deep in the money; holders can exercise and sell.
- ZEC volatility: ZEC ranged $185-$1,693 over the past year; the stock is a leveraged bet on it.
- Premium compression: the 1.7x premium can shrink even if ZEC holds.
- Legacy biotech: no product revenue; R&D and overhead continue.
Judgement
Justified. The -36% from the Sep 25 high follows ZEC's ~27% drop plus some compression of the premium; there is no company-specific bad news. Even after the drop, the stock trades at about 1.7x fully diluted NAV, so it is not cheap against its ZEC. The basic-share "discount" that shows up in some trackers is not real once the warrants are counted. Direction from here depends almost entirely on ZEC.
Sources
- https://www.sec.gov/Archives/edgar/data/1509745/000110465926094449/cyph-20260630x10q.htm
- https://www.sec.gov/Archives/edgar/data/1509745/000110465926060662/cyph-20260331x10q.htm
- https://www.cypherpunk.com/
- https://www.coingecko.com/en/treasuries/companies/cypherpunk-technologies
- https://www.prnewswire.com/news-releases/cypherpunk-accelerates-zcash-accumulation-increases-treasury-holdings-to-290-062-67-zec-302650408.html
- https://www.prnewswire.com/news-releases/cypherpunk-purchases-additional-18-million-of-zec-bringing-total-network-percentage-to-1-43-302617999.html
- https://www.stocktitan.net/news/CYPH/cypherpunk-technologies-reports-first-quarter-2026-financial-vi9656ah30jm.html
- https://www.sec.gov/Archives/edgar/data/0001509745/000110465925109820/tm2530735d1_ex99-1.htm
- https://seekingalpha.com/article/4939988-cypherpunk-technologies-looks-fully-valued-after-zcash-fueled-surge